These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 7181463)
1. [Effect of crystallinity on the rate of solution of oxytetracycline hydrochloride]. Grakovskaia LK; Nesterova LIa Antibiotiki; 1982 Nov; 27(11):815-20. PubMed ID: 7181463 [TBL] [Abstract][Full Text] [Related]
2. Crystal modification of dipyridamole using different solvents and crystallization conditions. Adhiyaman R; Basu SK Int J Pharm; 2006 Sep; 321(1-2):27-34. PubMed ID: 16842943 [TBL] [Abstract][Full Text] [Related]
3. Surface characteristics and dissolution behavior of plasma-sprayed hydroxyapatite coating. Sun L; Berndt CC; Khor KA; Cheang HN; Gross KA J Biomed Mater Res; 2002 Nov; 62(2):228-36. PubMed ID: 12209943 [TBL] [Abstract][Full Text] [Related]
4. [Effect of auxiliary substances on the bioavailability of tetracycline hydrochloride capsules (an in vitro study)]. Grakovskaia LK; Nesterova LIa; Okhotnikova VF; Zak AF; Ermolova OB Antibiotiki; 1978 Mar; 23(3):215-9. PubMed ID: 637528 [TBL] [Abstract][Full Text] [Related]
5. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297 [TBL] [Abstract][Full Text] [Related]
6. Nanoscale cellulose films with different crystallinities and mesostructures--their surface properties and interaction with water. Aulin C; Ahola S; Josefsson P; Nishino T; Hirose Y; Osterberg M; Wågberg L Langmuir; 2009 Jul; 25(13):7675-85. PubMed ID: 19348478 [TBL] [Abstract][Full Text] [Related]
7. [Study of the effect of the oxytetracycline crystallization conditions on the process indices]. Lin'kov GI; Zhukovskaia SA Antibiotiki; 1975 Jun; 20(7):591-5. PubMed ID: 5049 [TBL] [Abstract][Full Text] [Related]
8. Exploring solid forms of oxytetracycline hydrochloride. Bueno MS; Miñambres GG; Bongioanni A; Chattah AK; Aiassa V; Longhi MR; Garnero C Int J Pharm; 2020 Jul; 585():119496. PubMed ID: 32504775 [TBL] [Abstract][Full Text] [Related]
9. [Bioavailability of levomycetin preparations for oral use]. Batuashvili TA; Zak AF Antibiotiki; 1983 Oct; 28(10):751-4. PubMed ID: 6651263 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach. Mutalik S; Anju P; Manoj K; Usha AN Int J Pharm; 2008 Feb; 350(1-2):279-90. PubMed ID: 17945447 [TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of a new polymorphic form and a solvate of glibenclamide. Hassan MA; Sheikh Salem M; Sallam E; al-Hindawi MK Acta Pharm Hung; 1997; 67(2-3):81-8. PubMed ID: 9223758 [TBL] [Abstract][Full Text] [Related]
12. Improvement of physicomechanical properties of carbamazepine by recrystallization at different pH values. Javadzadeh Y; Mohammadi A; Khoei NS; Nokhodchi A Acta Pharm; 2009 Jun; 59(2):187-97. PubMed ID: 19564143 [TBL] [Abstract][Full Text] [Related]
13. The effect of crystal morphology and mill type on milling induced crystal disorder. Chikhalia V; Forbes RT; Storey RA; Ticehurst M Eur J Pharm Sci; 2006 Jan; 27(1):19-26. PubMed ID: 16246535 [TBL] [Abstract][Full Text] [Related]